Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses

SIMPLE SUMMARY: Although cancer immunotherapy has become a “game changer” in treating LUSC patients, challenges still prevail due to the heterogeneous response and insufficient predictive biomarkers. Recently, NSD3, a neighbor gene of FGFR1, was identified as a key genetic driver of LUSC tumorigenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Duo, Liu, Shengchen, Wu, Xi, Marti, Thomas M., Dorn, Patrick, Schmid, Ralph A., Peng, Ren-Wang, Shu, Yongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599511/
https://www.ncbi.nlm.nih.gov/pubmed/36291782
http://dx.doi.org/10.3390/cancers14204997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599511/
https://www.ncbi.nlm.nih.gov/pubmed/36291782
http://dx.doi.org/10.3390/cancers14204997

Ejemplares similares